CoChat

Growth Differentiation Factor-15 is Not Modified by Sacubitril/Valsartan and is an Independent Marker of Risk in Patients with Heart Failure and Reduced Ejection Fraction: The PARADIGM-HF Trial

Open access
Bouabdallaoui, Nadia, Claggett, Brian, Zile, Michael R., McMurray, John J.V., O'Meara, Eileen, Packer, Milton, Prescott, Margarett F., Swedberg, Karl, Solomon, Scott D., Rouleau, Jean L., for the PARADIGM-HF Investigators and Committees · 2018 · European Journal of Heart Failure
Cited by 83

The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.

Abstract

Aims: Growth differentiation factor-15 (GDF-15) is associated with adverse prognosis in cardiovascular (CV) and non-CV diseases. We evaluated the association of GDF-15 with CV and non-CV outcomes in the PARADIGM-HF trial. Methods and results: In 1935 patients with heart failure and reduced ejection fraction (HFrEF) in PARADIGM-HF, median GDF-15 values were elevated and similar in sacubitril/valsartan and enalapril patients (1626 ng/L and 1690 ng/L, respectively). Diabetes, age, creatinine, high-sensitive troponin T, N-terminal pro-B-type natriuretic peptide, and New York Heart Association class III/IV were most strongly associated with elevated GDF-15 values (all P < 0.001) (adjusted R2 = 0.3857). Baseline GDF-15 and changes in GDF-15 at both 1 month and 8 months (log-transformed) were associated with subsequent mortality and CV events. Each 20% increment in baseline GDF-15 value was associated with a higher risk of mortality [adjusted hazard ratio (HR) 1.13, 95% confidence interval (CI) 1.08–1.18, P < 0.001], the combined endpoint of CV death or hospitalization for heart failure (adjusted HR 1.09, 95% CI 1.05–1.14, P < 0.001) and heart failure death (adjusted HR 1.16, 95% CI 1.05–1.28, P < 0.001). Changes in GDF-15 were not influenced by assigned therapy (all P-values ≥ 0.1). Conclusion: In patients with ambulatory HFrEF, GDF-15 is not modified by sacubitril/valsartan and is strongly associated with mortality and CV outcomes, suggesting that GDF-15 is a marker of poor outcomes in these patients. Clinical Trial Registration: ClinicalTrials.gov Identifier NCT01035255.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1002/ejhf.1301

Cites

4 of 4 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 4 references

Cited by

See all 83

Metadata

Authors
Bouabdallaoui, N., Claggett, B., Zile, M. R., McMurray, J. J. V., O'Meara, E., Packer, M., Prescott, M. F., Swedberg, K., Solomon, S. D., Rouleau, J. L., & for the PARADIGM-HF Investigators and Committees
Venue
European Journal of Heart Failure
Published
2018-09-11
Volume
20
Issue
12
Pages
1701-1709
ISSN
  • 1388-9842 (ISSN-L)
  • 1879-0844
OpenAlex
W2891979996
Cited by
83
References
4
FWCI
5.69
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Growth Differentiation Factor-15 is Not Modified by Sacubitril/Valsartan and is an Independent Marker of Risk in Patients with Heart Failure and Reduced Ejection Fraction: The PARADIGM-HF Trial. https://app.cochat.ai/papers/10.1002/ejhf.1301
The paper
Bouabdallaoui, N., Claggett, B., Zile, M. R., McMurray, J. J. V., O'Meara, E., Packer, M., Prescott, M. F., Swedberg, K., Solomon, S. D., Rouleau, J. L., & for the PARADIGM-HF Investigators and Committees. (2018). Growth Differentiation Factor-15 is Not Modified by Sacubitril/Valsartan and is an Independent Marker of Risk in Patients with Heart Failure and Reduced Ejection Fraction: The PARADIGM-HF Trial. European Journal of Heart Failure. https://doi.org/10.1002/ejhf.1301

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.